 |
| |
| |
| News |
|
| |
| |
ACHILLION APPOINTS DR. DAVID APELIAN AS CHIEF MEDICAL OFFICER AND EXPANDS CLINICAL OPERATIONS TEAM |
|
| 5/15/2013 |
| ACHILLION APPOINTS DR. DAVID APELIAN AS CHIEF MEDICAL OFFICER AND EXPANDS CLINICAL OPERATIONS TEAM |
|
more
|
| |
| |
|
|
| |
| |
CELATOR PHARMACEUTICALS RAISES $32.5 MILLION COMPLETING A $39.3 MILLION PRIVATE PLACEMENT FINANCING |
|
| 4/30/2013 |
| CELATOR PHARMACEUTICALS RAISES $32.5 MILLION COMPLETING A $39.3 MILLION PRIVATE PLACEMENT FINANCING |
|
more
|
| |
| |
|
|
| |
| |
PHASE I DATA EVALUATING SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE WEEKLY DOSES OF DALBAVANCIN PRESENTED AT THE 23RD ANNUAL ECCMID MEETING |
|
| 4/29/2013 |
| PHASE I DATA EVALUATING SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE WEEKLY DOSES OF DALBAVANCIN PRESENTED AT THE 23RD ANNUAL ECCMID MEETING |
|
more
|
| |
| |
|
|
| |
| |
ESPERION THERAPEUTICS COMPLETES $33 MILLION PREFERRED FINANCING TO ADVANCE ITS NOVEL ORAL LDL-C LOWERING THERAPY TO LATER STAGE CLINICAL TRIALS |
|
| 4/25/2013 |
| ESPERION THERAPEUTICS COMPLETES $33 MILLION PREFERRED FINANCING TO ADVANCE ITS NOVEL ORAL LDL-C LOWERING THERAPY TO LATER STAGE CLINICAL TRIALS |
|
more
|
| |
| |
|
|
| |
| |
TRANZYME PHARMA AND OCERA THERAPEUTICS ANNOUNCE MERGER AGREEMENT $20M COMMITTED PIPE FINANCING TO CLOSE WITH MERGER |
|
| 4/24/2013 |
| TRANZYME PHARMA AND OCERA THERAPEUTICS ANNOUNCE MERGER AGREEMENT $20M COMMITTED PIPE FINANCING TO CLOSE WITH MERGER |
|
more
|
| |
| |
|
|
| |
| |
ORAYA THERAPEUTICS' INTREPID STUDY PUBLISHED IN OPTHALMOLOGY, THE OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF OPTHALMOLOGY |
|
| 4/18/2013 |
| ORAYA THERAPEUTICS' INTREPID STUDY PUBLISHED IN OPTHALMOLOGY, THE OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF OPTHALMOLOGY |
|
more
|
| |
| |
|
|
| |
| |
VERACYTE ANNOUNCES THAT NEW STUDY SUGGESTS THE NUMBER OF PATIENTS AT RISK FOR UNNECESSARY THYROID SURGERY IS LIKELY ON THE RISE |
|
| 4/17/2013 |
| VERACYTE ANNOUNCES THAT NEW STUDY SUGGESTS THE NUMBER OF PATIENTS AT RISK FOR UNNECESSARY THYROID SURGERY IS LIKELY ON THE RISE |
|
more
|
| |
| |
|
|
| |
| |
THE UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM AND RIGHTCARE SOLUTIONS, INC. ANNOUNCE EXPANDED PARTNERSHIP TO REDUCE READMISSIONS |
|
| 4/3/2013 |
| THE UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM AND RIGHTCARE SOLUTIONS, INC. ANNOUNCE EXPANDED PARTNERSHIP TO REDUCE READMISSIONS |
|
more
|
| |
| |
|
|
| |
| |
DICERNA ANNOUNCES PATENT ISSUANCE FOR DSIRNAS DIRECTED AT THE KRAS GENE, A KEY CANCER REGULATOR |
|
| 3/19/2013 |
| DICERNA ANNOUNCES PATENT ISSUANCE FOR DSIRNAS DIRECTED AT THE KRAS GENE, A KEY CANCER REGULATOR |
|
more
|
| |
| |
|
|
| |
| |
LITHERA INITIATES PHASE 2B CLINICAL TRIAL OF LIPO-202 TARGETING AESTHETIC REDUCTION OF SUBCUTANEOUS ABDOMINAL FAT |
|
| 3/12/2013 |
| LITHERA INITIATES PHASE 2B CLINICAL TRIAL OF LIPO-202 TARGETING AESTHETIC REDUCTION OF SUBCUTANEOUS ABDOMINAL FAT |
|
more
|
| |
| |
|
|
| |
| |
DOMAIN ASSOCIATES AND ELITE CONSULTING COLLABORATE TO CREATE AND INVEST IN LIFE SCIENCE COMPANIES IN CHINA |
|
| 3/3/2013 |
| DOMAIN ASSOCIATES AND ELITE CONSULTING COLLABORATE TO CREATE AND INVEST IN LIFE SCIENCE COMPANIES IN CHINA |
|
more
|
| |
| |
|
|
| |
| |
ADYNXX ENROLLS FIRST PATIENT IN PHASE 2 PROOF-OF-CONCEPT STUDY FOR AYX1 |
|
| 2/25/2013 |
| ADYNXX ENROLLS FIRST PATIENT IN PHASE 2 PROOF-OF-CONCEPT STUDY FOR AYX1 |
|
more
|
| |
| |
|
|
| |
| |
CUBIST ANNOUNCES EXCLUSIVE OPTION TO ACQUIRE ADYNXX |
|
| 2/25/2013 |
| CUBIST ANNOUNCES EXCLUSIVE OPTION TO ACQUIRE ADYNXX |
|
more
|
| |
| |
|
|
| |
| |
DURATA THERAPEUTICS ANNOUNCES PRELIMINARY, TOPLINE PHASE 3 CLINICAL TRIAL |
|
| 2/25/2013 |
| DURATA THERAPEUTICS ANNOUNCES PRELIMINARY, TOPLINE PHASE 3 CLINICAL TRIAL |
|
more
|
| |
| |
|
|
| |
| |
ADYNXX - PHASE 1 DATA - SEPTEMBER 5, 2012 |
|
| 9/5/2012 |
| Adynxx - Phase 1 Data - September 5, 2012 |
|
more
|
| |
| |
|
|
| |
| |
DICERNA PHARMACEUTICALS ANNOUNCES SECOND DSIRNA THERAPEUTIC ONCOLOGY CANDIDATE, ACHIEVES DEVELOPMENT MILESTONE |
|
| 8/8/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
ADYNXX COMPLETES ENROLLMENT IN PHASE 1 CLINICAL STUDY OF LEAD THERAPEUTIC FOR TREATMENT OF PAIN, AYX1 |
|
| 8/7/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
DOMAIN ASSOCIATES & RUSNANO ANNOUNCE FIRST JOINT INVESTMENT |
|
| 7/24/2012 |
| DOMAIN ASSOCIATES & RUSNANO ANNOUNCE FIRST JOINT INVESTMENT |
|
more
|
| |
| |
|
|
| |
| |
THE LEUKEMIA & LYMPHOMA SOCIETY AND CELATOR PHARMACEUTICALS ANNOUNCE $5 MILLION PARTNERSHIP |
|
| 7/2/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
VERACYTE ANNOUNCES STUDY RESULTS PUBLISHED ONLINE IN NEW ENGLAND JOURNAL OF MEDICINE |
|
| 6/25/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
SYNDAX STARTS PHASE 1/2 STUDY OF ENTINOSTAT IN COMBINATION WITH LAPATINIB IN HER2‐POSITIVE METASTATIC BREAST CANCER |
|
| 4/9/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
SYNDAX APPOINTS ARTHUR M. PAPPAS TO BOARD OF DIRECTORS |
|
| 4/5/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
ARIOSA DIAGNOSTICS ANNOUNCES COMPLETION OF LABORATORY-DEVELOPED TEST STUDY FOR THE HARMONY™ PRENATAL TEST |
|
| 3/26/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
DURATA THERAPEUTICS, INC. FILES REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING |
|
| 3/23/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
PSIVIDA ANNOUNCES SECOND TECH EVALUATION AGREEMENT WITH ITS BIOERODIBLE DURASERT TECHNOLOGY AGREEMENT WITH NEURON SYSTEMS FOCUSES ON DRY AMD |
|
| 3/13/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
RUSNANO AND DOMAIN TO COLLABORATE ON INVESTMENTS IN HEALTH SCIENCES PROJECTS |
|
| 3/6/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
SEQUENT MEDICAL ANNOUNCES CLOSING OF $26.0 MILLION VENTURE FINANCING |
|
| 3/6/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
APPLIED PROTEOMICS APPOINTS PETER KLEMM AS CEO FOLLOWING SERIES B FINANCING OF $22.5 MILLION |
|
| 2/7/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
DEXCOM AND TANDEM DIABETES CARE ANNOUNCE CGM DEVELOPMENT AND COMMERCIALIZATION AGREEMENT |
|
| 2/2/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
GENZYME AND VERACYTE ANNOUNCE GLOBAL CO-PROMOTION AGREEMENT TO DELIVER PERSONALIZED SOLUTION FOR THYROID PATIENTS |
|
| 1/20/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
SKINMEDICA ACQUIRES LEADING PROFESSIONAL MINERAL MAKEUP COMPANY COLORESCIENCE |
|
| 1/9/2012 |
|
|
more
|
| |
| |
|
|
| |
| |
TANDEM DIABETES CARE ANNOUNCES FDA CLEARANCE OF THE T:SLIM™ INSULIN DELIVERY SYSTEM |
|
| 11/16/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
CLOVIS ONCOLOGY ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING |
|
| 11/16/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
DICERNA AWARDED NOTICE OF ALLOWANCE BY U.S. PATENT AND TRADEMARK OFFICE FOR PATENT CLAIMS BROADLY COVERING DICER SUBSTRATE SIRNA MOLECULES |
|
| 11/1/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
DURATA THERAPEUTICS INITIATES ENROLLMENT IN DISCOVER-2 |
|
| 9/29/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® PHARMACEUTICALS GRANTED U.S. PATENT COVERING LEAD CANCER PRODUCT |
|
| 9/21/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN AND FDA IDENTIFY A CLEAR AND FEASIBLE PATH TO APPROVAL FOR CONTRAVE |
|
| 9/20/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
IMPACTRX ACQUIRES TARGETRX |
|
| 9/13/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
PROTEINSIMPLE REINVENTS THE WESTERN BLOT |
|
| 8/30/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
ZOGENIX REPORTS POSITIVE PHASE 3 RESULTS FOR ZOHYDRO |
|
| 8/17/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
ACHILLION REPORTS SECOND QUARTER AND SIX MONTH 2011 FINANCIAL RESULTS |
|
| 8/8/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
ALIMERA SCIENCES REPORTS SECOND QUARTER 2011 FINANCIAL RESULTS |
|
| 8/4/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
CADENCE PHARMACEUTICALS REPORTS SECOND QUARTER 2011 FINANCIAL RESULTS |
|
| 8/3/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
APNEX MEDICAL, INC. RECEIVES FDA APPROVAL FOR PIVOTAL CLINICAL STUDY FOR |
|
| 8/2/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
ALIMERA SCIENCES APPOINTS JAMES R. LARGENT TO ITS BOARD OF DIRECTORS |
|
| 8/1/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
BENVENUE MEDICAL ADDS TWO SENIOR EXECUTIVES IN SALES AND MARKETING |
|
| 7/19/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
ACHILLION ANNOUNCES INITIATION OF PHASE 1 TRIAL OF ACH-2928 FOR THE TREATMENT OF HEPATITIS C |
|
| 7/11/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
ZOGENIX ENTERS $30 MILLION ROYALTY FINANCING AGREEMENT WITH COWEN HEALTHCARE ROYALTY PARTNERS |
|
| 6/30/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
INTEGENX ANNOUNCES EARLY ACCESS PARTNERSHIP FOR ITS RAPIDHIT™ 200 HUMAN DNA IDENTIFICATION SYSTEM |
|
| 6/20/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
BioNanomatrix Opens West Coast Headquarters, Expands Senior Team |
|
| 6/15/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
SYNDAX PHARMACEUTICALS ELECTS ARLENE MORRIS TO BOARD OF DIRECTORS |
|
| 6/8/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® PRESENTS POSITIVE DATA FROM PHASE 2 STUDY OF CPX-351 |
|
| 6/6/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
ASMACURE LTÉE APPOINTS PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRY VETERAN MARTIN DRISCOLL AS CEO |
|
| 6/3/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
CLOVIS ONCOLOGY, INC. RECEIVES LICENSE FOR WORLDWIDE DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO PFIZER’S ORAL AND IV PARP INHIBITOR PF-01367338 |
|
| 6/2/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
SYNDAX PHARMACEUTICALS ANNOUNCES ISSUANCE OF US PATENT FOR ENTINOSTAT |
|
| 6/2/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
DURATA THERAPEUTICS INITIATES PHASE 3 STUDY OF DALBAVANCIN FOR THE TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS |
|
| 4/18/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
VENTIRX PRESENTS POSITIVE CLINICAL AND PRE-CLINICAL DATA AT AMERICAN ACADEMY OF ALLERGY & IMMUNOLOGY ANNUAL MEETING |
|
| 3/21/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
HUMAN GENOME SCIENCES AND FIVEPRIME THERAPEUTICS ANNOUNCE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR NOVEL ANTI-CANCER DRUG |
|
| 3/16/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
MIRADRY BY MIRAMAR LABS RECEIVES FDA 510(K) CLEARANCE |
|
| 2/8/2011 |
|
|
more
|
| |
| |
|
|
| |
| |
SYNDAX PHARMACEUTICALS’ ENTINOSTAT PLUS ERLOTINIB IMPROVES SURVIVAL IN SELECT NSCLC PATIENTS |
|
| 12/9/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® PRESENTS POSITIVE DATA FROM PHASE 2 STUDY OF CPX-351 AT ASH |
|
| 12/7/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
ATYR PHARMA SECURES $23M FINANCING |
|
| 10/26/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® PHARMACEUTICALS COMPLETES ENROLLMENT IN A SECOND PHASE 2 TRIAL OF CPX-351 IN ACUTE MYELOID LEUKEMIA |
|
| 10/26/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
FIVE PRIME THERAPEUTICS, INC. ELECTS FRANKLIN BERGER TO ITS BOARD OF DIRECTORS |
|
| 9/27/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
CARTICEPT MEDICAL ANNOUNCES PARTNERSHIP WITH ATLANTA FALCONS |
|
| 9/23/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
TRAGARA PHARMACEUTICALS INITIATES PHASE 1 CLINICAL PROGRAM FOR TG02 |
|
| 9/9/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN AND TAKEDA ENTER INTO PARTNERSHIP TO COMMERCIALIZE CONTRAVE IN NORTH AMERICA |
|
| 9/2/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® PHARMACEUTICALS RAISES $20 MILLION IN SERIES D FINANCING |
|
| 9/1/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
OTONOMY CLOSES $38.5M SERIES B FINANCING |
|
| 8/30/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
ACHILLION ANNOUNCES PRIVATE PLACEMENT OF $50 MILLION |
|
| 8/18/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
DICERNA CLOSES $25 MILLION SERIES B FINANCING |
|
| 8/11/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
ILLUMINA ACQUIRES HELIXIS FOR UP TO $105 MILLION |
|
| 7/27/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR EXPANDS RESEARCH AGREEMENT WITH CEPHALON, INC. |
|
| 6/21/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
ESPERION TAPS TRANSGENRX HEART THERAPY PROTEINS |
|
| 6/21/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
NUON THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE 2A STUDY IN HYPERURICEMIA |
|
| 6/16/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® PHARMACEUTICALS ANNOUNCES DATA ON REMISSIONS WITH CPX-351 FOLLOWING INDUCTION FAILURE |
|
| 6/7/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
FIVE PRIME THERAPEUTICS, INC. AND FAST FORWARD, LLC COLLABORATE TO SPEED NEW TREATMENTS TO PEOPLE WITH MULTIPLE SCLEROSIS |
|
| 5/25/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
CODA THERAPEUTICS ACHIEVES POSITIVE PHASE 2 EFFICACY OF NEXAGON® IN CHRONIC VENOUS LEG ULCERS |
|
| 5/25/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
CLOVIS ONCOLOGY AND AVILA THERAPEUTICS SIGN $209 MILLION PARTNERSHIP |
|
| 5/25/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
ASTUTE MEDICAL ANNOUNCES $26.5 MILLION SERIES B FINANCING |
|
| 5/10/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY OF CPX-351 IN ACUTE MYELOID LEUKEMIA |
|
| 5/3/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
ALIMERA SCIENCES PRICES INITIAL PUBLIC OFFERING |
|
| 4/23/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® PHARMACEUTICALS PRESENTS NEW DATA ON TWO NANO-SCALE DELIVERY PLATFORMS AT AACR |
|
| 4/22/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® PHARMACEUTICALS RECEIVES NOTICE OF ALLOWANCE ON U.S. PATENT FOR COMBIPLEX TECHNOLOGY PLATFORM |
|
| 4/12/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
ZOGENIX INITIATES PIVOTAL PHASE 3 CLINICAL TRIAL FOR NOVEL FORMULATION OF ORAL CONTROLLED-RELEASE HYDROCODONE |
|
| 3/17/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
MICROCHIP BIOTECHNOLOGIES CHANGES NAME TO INTEGENX |
|
| 3/10/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
ZOGENIX APPOINTS NEW CHIEF FINANCIAL OFFICER |
|
| 3/1/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
FIVE PRIME THERAPEUTICS, INC. ANNOUNCES MILESTONE FOR THERAPEUTIC PROGRAM |
|
| 2/24/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® SELECTED TO PARTICIPATE IN NCI’S NANOTECHNOLOGY CHARACTERIZATION LABORATORY ASSAY CASCADE |
|
| 2/17/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
AFFERENT PHARMACEUTICALS NAMES BRUCE MCCARTHY, M.D. AS CEO |
|
| 1/26/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
VENTIRX RAISES $25 MILLION IN SERIES A EXTENSION FINANCING |
|
| 1/12/2010 |
|
|
more
|
| |
| |
|
|
| |
| |
NOVARTIS TO ACQUIRE CORTHERA |
|
| 12/23/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
ROCHE LICENSES FIRST-IN-CLASS TREATMENTS FOR CHRONIC PAIN TO AFFERENT PHARMACEUTICALS; AFFERENT SECURES $23M IN SERIES A FINANCING |
|
| 12/16/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
CUBIST PHARMACEUTICALS TO ACQUIRE CALIXA THERAPEUTICS |
|
| 12/14/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
GENVAULT ANNOUNCES SUPPLY AGREEMENT WITH LIFE TECHNOLOGIES |
|
| 12/9/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
PIVOTAL TRIAL DATA DEMONSTRATE NEUROPACE RNS® SYSTEM |
|
| 12/7/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR PRESENTS INTERIM DATA FROM PHASE 2 STUDY OF CPX-351 IN NEWLY DIAGNOSED AML AT ASH |
|
| 12/7/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
APNEX MEDICAL, INC. RAISES ADDITIONAL $14 MILLION |
|
| 12/2/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
ESPERION THERAPEUTICS INITIATES PHASE I CLINICAL STUDY FOR ETC-1002 |
|
| 11/13/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR COMPLETES ENROLLMENT EARLY IN PHASE 2 STUDY OF CPX-351 IN NEWLY DIAGNOSED AML |
|
| 10/12/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
CORTHERA’S RELAXIN RECEIVES FDA FAST TRACK DESIGNATION FOR THE TREATMENT OF ACUTE HEART FAILURE |
|
| 10/1/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
REGADO BIOSCIENCES ANNOUNCES FIRST PATIENT ENROLLED IN RADAR (Phase 2b) STUDY OF REG1 ANTICOAGULATION SYSTEM |
|
| 9/9/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
DOMAIN ASSOCIATES LLC RAISES 8TH VENTURE FUND |
|
| 8/10/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
ZOGENIX GETS FDA APPROVAL FOR SUMAVEL DOSEPRO FOR THE TREATMENT OF ACUTE MIGRAINE AND CLUSTER HEADACHE |
|
| 7/16/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
CALIXA ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL OF ITS ANTIBIOTIC, CXA-101, IN PATIENTS WITH COMPLICATED URINARY TRACT INFECTIONS |
|
| 6/30/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR PRESENTS DATA ON THE ACTIVITY OF CPX-351 AGAINST LEUKEMIA AT THE EUROPEAN HEMATOLOGY ASSOCIATION CONGRESS |
|
| 6/8/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
RELAXIN FOR AHF IS THE STRONGEST PREDICTOR OF IMPROVED LONGER-TERM OUTCOMES FOLLOWING HOSPITAL DISCHARGE WHEN COMPARED TO OTHER VARIABLES |
|
| 6/1/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
RESULTS AND ADDITIONAL ANALYSES FROM EFFICACY AND SAFETY STUDY OF CORTHERA’S RELAXIN IN ACUTE HEART FAILURE TO BE PRESENTED AT HEART FAILURE CONGRESS |
|
| 5/28/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
CLOVIS ONCOLOGY RAISES $145 MILLION IN START-UP FINANCING |
|
| 5/21/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® PHARMACEUTICALS INITIATES RESEARCH AGREEMENT WITH CEPHALON, INC. |
|
| 5/21/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® PHARMACEUTICALS TO PRESENT AT 2009 BIO INTERNATIONAL CONVENTION |
|
| 5/13/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
ALTEA THERAPEUTICS ANNOUNCES SENIOR R&D MANAGEMENT APPOINTMENTS |
|
| 5/5/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
EVOKE PHARMA, INC. INITIATES PHASE 2B METOCLOPRAMIDE INTRANASAL TRIAL (MINT) IN PATIENTS WITH DIABETIC GASTROPARESIS |
|
| 5/5/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR® PHARMACEUTICALS PRESENTS NEW DATA ON CPX-351 and CPX-1 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH |
|
| 4/22/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
VENTIRX INITIATES PHASE I TRIAL OF VTX-1463, A NOVEL TLR8 AGONIST FOR THE TREATMENT OF ALLERGIC RHINITIS |
|
| 4/16/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
SANOFI-AVENTIS TO ACQUIRE BIPAR SCIENCES |
|
| 4/15/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
ALTEA THERAPEUTICS ANNOUNCES AGREEMENT WITH AMYLIN AND LILLY FOR AN INVESTIGATIONAL TRANSDERMAL EXENATIDE |
|
| 4/1/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
RESULTS FROM STUDY SHOW PROMISING EFFICACY AND SAFETY RESULTS FOR CORTHERA’S RELAXIN IN ACUTE HEART FAILURE |
|
| 3/29/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
MARINUS PHARMACEUTICALS, INC. ANNOUNCES POSITIVE RESULTS OF ITS PHASE 2 CLINICAL TRIAL OF GANAXOLONE AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSE |
|
| 3/3/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
NOVALAR ANNOUNCES THE LAUNCH OF ORAVERSE™ THE FIRST DENTAL ANESTHESIA REVERSAL AGENT |
|
| 2/27/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
ASCENTA THERAPEUTICS ANNOUNCES POSITIVE PRELIMINARY RESULTS WITH AT-101 IN DOCETAXEL REFACTORY PROSTATE CANCER |
|
| 2/27/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
MERITAGE PHARMA INITIATES PHASE 2B CLINICAL TRIAL OF ORAL VISCOUS BUDESONIDE FOR PEDIATRIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS |
|
| 1/22/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
LEUKEMIA & LYMPHOMA SOCIETY AND CELATOR ANNOUNCE PARTNERSHIP TO ACCELERATE DEVELOPMENT OF CPX-351 FOR AML |
|
| 1/22/2009 |
|
|
more
|
| |
| |
|
|
| |
| |
VENTIRX PHARMACEUTICALS COMMENCES PHASE I CLINICAL TRIAL OF VTX-2337, A NOVEL TLR8 AGONIST FOR THE TREATMENT OF ONCOLOGY |
|
| 12/4/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR PHARMACEUTICALS TO PRESENT AT PIPER JAFFRAY HEALTH CARE CONFERENCE and MID-ATLANTIC CAPITAL CONFERENCE |
|
| 11/25/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR PHARMACEUTICALS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2 STUDY WITH CPX-351 |
|
| 11/18/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
INTERIM ANALYSIS OF TOP-LINE DATA FROM PHASE II/III STUDY SHOWS FAVORABLE EFFICACY & SAFETY FOR CORTHERA’S RELAXIN IN ACUTE HEART FAILURE |
|
| 11/10/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
BIPAR SCIENCES' LEAD COMPOUND SELECTED AS TOP 10 ONCOLOGY DRUG CANDIDATE |
|
| 10/28/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
MARINUS COMPLETES TWO PHASE 2 MILESTONES FOR GANAXOLONE IN EPILEPSY |
|
| 10/7/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ALIMERA REPORTS RESULTS FROM THE SIX-MONTH INTERIM READOUT OF THE HUMAN PK ILUVIEN™ STUDY |
|
| 10/1/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
OCEANA THERAPEUTICS COMMENCES OPERATIONS AFTER COMPLETING SERIES A FINANCING ROUND |
|
| 9/29/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
GI DYNAMICS ANNOUNCES SHORT-TERM WEIGHT LOSS RESULTS IN MORBIDLY OBESE PATIENTS |
|
| 9/26/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
GI DYNAMICS ANNOUNCES DATA THAT SHOWS ENDOBARRIER REDUCES HBA1C IN PATIENTS WITH TYPE 2 DIABETES |
|
| 9/16/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
FIVEPRIME INITIATES PHASE I OF FP-1039 IN PATIENTS WITH ADVANCED CANCERS |
|
| 9/8/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
COLUCID PRESENTS PHASE II RESULTS OF COL-144 AT THE EUROPEAN HEADACHE AND MIGRAINE TRUST INTERNATIONAL CONGRESS 2008 |
|
| 9/5/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
REGADO BIOSCIENCES REPORTS CLINICAL RESULTS FOR REG1 ANTICOAGULATION SYSTEM AT EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2008 |
|
| 9/4/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR RECEIVES ORPHAN DRUG DESIGNATION FOR CPX-351 |
|
| 9/4/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
MARINUS APPOINTS JOHN KRAYACICH AS PRESIDENT AND CEO |
|
| 8/5/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ZOGENIX CLOSES $18 MILLION FINANCING WITH OXFORD FINANCE CORPORATION AND CIT HEALTHCARE LLC |
|
| 8/5/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
DAVID J. MAZZO, PH.D., JOINS REGADO BIOSCIENCES AS PRESIDENT AND CEO |
|
| 8/4/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR RAISES SERIES C FINANCING IN EXCESS OF $22.5 MILLION |
|
| 7/28/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ALTEA PARTNERS TRANSDERMAL PRODUCT WITH HOSPIRA |
|
| 7/2/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
COLUCID CLOSES $25 MILLION SERIES B FINANCING |
|
| 7/1/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ZOGENIX TO PRESENT DOSEPRO RESULTS AT ANNUAL AMERICAN HEADACHE SOCIETY MEETING |
|
| 6/28/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ALIMERA REPORTS RESULTS FROM THE THREE-MONTH INTERIM READOUT OF THE HUMAN PK MEDIDUR FA STUDY |
|
| 6/26/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
VANDA ANNOUNCES POSITIVE TOP-LINE PHASE III DATA OF TASIMELTON IN ADULTS WITH CHRONIC INSOMNIA |
|
| 6/26/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELL BIOSCIENCES ANNOUNCES NEW LEADERSHIP |
|
| 6/24/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
MERITAGE PHARMA CLOSES $22.5 MILLION SERIES A FINANCING |
|
| 6/16/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
MERITAGE ACQUIRES PEDIATRIC GASTROINTESTINAL PROGRAM FROM VERUS PHARMACEUTICALS |
|
| 6/16/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
GIDYNAMICS PRESENTS INITIAL RESULTS AT ADA |
|
| 6/13/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
GENVAULT CORPORATION RAISES $13 MILLION OF VENTURE FINANCING |
|
| 6/9/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN: CONTRAVE MAY REVERSE THE INCIDENCE OF METABOLIC SYNDROME |
|
| 6/7/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
VANDA AND LABCORP COLLABORATE TO OFFER GENETIC TESTS |
|
| 6/5/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR REPORTS POSITIVE PHASE 2 DATA FOR CPX-1 IN COLORECTAL CANCER |
|
| 6/3/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
VENTIRX APPOINTS DR. ELLIOT GROSSBARD TO BOARD OF DIRECTORS |
|
| 5/20/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
FIVEPRIME AND PFIZER ENTER ONCOLOGY AND DIABETES COLLABORATION |
|
| 5/20/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
NOVALAR RECEIVES FDA APPROVAL FOR ORAVERSE |
|
| 5/12/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR PHARMACEUTICALS APPOINTS SCOTT JACKSON AS CEO |
|
| 5/9/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
FIVE PRIME REPORTS DISCOVERY OF IL-34, A NOVEL CYTOKINE |
|
| 5/8/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ESPERION THERAPEUTICS COMPLETES $22.75M SERIES A FINANCING |
|
| 5/1/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
NUON THERAPEUTICS INC. COMPLETES $27M SERIES B FINANCING |
|
| 4/28/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN COMPLETES ENROLLMENT OF SECOND PHASE III CONTRAVE TRIAL |
|
| 4/22/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
TARGETRX COMPLETES $9.6MM FINANCING ROUND |
|
| 4/7/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ORQIS MEDICAL PRESENTS MOMENTUM TRIAL RESULTS AT ACC |
|
| 4/1/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
DIOBEX ANNOUNCES PRESENTATION OF SCIENTIFIC POSTER AT ANNUAL MEETING OF AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS |
|
| 4/1/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
FDA ACCEPTS ZOGENIX NDA FILING |
|
| 3/19/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
ALIMERA SCIENCES CLOSES $30 MILLION SERIES C FINANCING |
|
| 3/18/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
DIOBEX AND CAMURUS SIGN LICENSE AGREEMENT FOR THE DEVELOPMENT OF DIO-901 IN FLUIDCRYSTAL EXTENDED RELEASE TECHNOLOGY |
|
| 3/18/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
SCIELE PHARMA ACQUIRES TWINJECT FROM VERUS PHARMACEUTICALS |
|
| 3/13/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
PHARMION SHAREHOLDERS APPROVE ACQUISTION BY CELGENE |
|
| 3/6/2008 |
|
|
more
|
| |
| |
|
|
| |
| |
REVA MEDICAL RAISES $42M |
|
| 12/10/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
CELGENE TO ACQUIRE PHARMION FOR $2.9B |
|
| 11/19/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
CELGENE TO ACQUIRE PHARMION FOR $2.9B |
|
| 11/19/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
CELGENE TO ACQUIRE PHARMION FOR $2.9B |
|
| 11/19/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
CELGENE TO ACQUIRE PHARMION FOR $2.9B |
|
| 11/19/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
CELGENE TO ACQUIRE PHARMION FOR $2.9B |
|
| 11/19/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
NOVALAR RAISES $30M IN SERIES D FINANCING |
|
| 10/26/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN RELEASES SUMMARY OF POSITIVE PHASE 2B CONTRAVE RESULTS IN OBESITY |
|
| 10/21/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
VERUS DIVESTS PEDIATRIC ASTHMA PROGRAM TO ASTRAZENECA |
|
| 10/8/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
VANDA SUBMITS NDA FOR ILOPERIDONE FOR SCHIZOPHRENIA |
|
| 10/8/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
ESPRIT PHARMA TO BE ACQUIRED BY ALLERGAN FOR $370M |
|
| 9/19/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR CLOSES $10M SERIES B FOLLOW-ON |
|
| 8/10/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
MERCK ACQUIRES NOVACARDIA FOR $350M PLUS CASH |
|
| 7/25/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
NOVALAR'S NV-101 NDA APPROVED |
|
| 6/19/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
APNEX MEDICAL, INC. RAISES $16.1 MILLION IN SERIES 'A' FINANCING |
|
| 5/14/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
MARINUS INITIATES PHASE IIB STUDY OF GANAXOLONE FOR ADULT PARTIAL SEIZURES |
|
| 5/10/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN THERAPEUTICS ANNOUNCES PRICING OF ITS INITIAL PUBLIC OFFERING |
|
| 4/27/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
ALIMERA SCIENCES' MEDIDUR(TM) TRIAL EXCEEDS 500 PATIENT MARK IN PHASE 3 TRIAL ENROLLMENT |
|
| 4/24/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
SYNDAX PHARMACEUTICALS LICENSES SELECTIVE HDAC INHIBITOR |
|
| 4/13/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
GENVAULT CORPORATION RAISES $18M FINANCING |
|
| 4/4/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
SYNDAX PHARMACEUTICALS CLOSES $40M SERIES A FINANCING |
|
| 4/3/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
DIOBEX ANNOUNCES SUCCESSFUL COMPLETION OF PHASE 2A TRIAL OF DIO-902, A NOVEL CORTISOL SYNTHESIS INHIBITOR FOR TYPE 2 DIABETES |
|
| 3/27/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
NOVALAR'S NV-101 PRODUCES POSITIVE PHASE II AND III RESULTS |
|
| 3/23/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
TRAGARA PHARMACEUTICALS ANNOUNCES CORPORATE LAUNCH AND SERIES A FINANCING |
|
| 3/14/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
VENTIRX SECURES $28.9MM SERIES A FINANCING |
|
| 3/7/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
ALTEA THERAPEUTICS REPORTS POSITIVE RESULTS FOR BASAL INSULIN TRANSDERMAL PATCH- DIABETES THERAPY |
|
| 3/2/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
FDA ACCEPTS PHARMION MYELOMA DRUG FOR REVIEW |
|
| 3/2/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
ALTEA THERAPEUTICS REPORTS POSITIVE RESULTS FOR BASAL INSULIN TRANSDERMAL PATCH- DIABETES THERAPY |
|
| 3/2/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
CoDa THERAPEUTICS SECURES $10M IN ADDITIONAL SERIES A FINANCING |
|
| 2/22/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
PHARMION ANNOUNCES FDA ACCEPTANCE OF IND FOR ORAL AZACITIDINE |
|
| 1/31/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
PHARMION CORPORATION ANNOUNCES FDA APPROVAL OF VIDAZA NDA SUPPLEMENT FOR IV ADMINISTRATION |
|
| 1/30/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
ZOGENIX: NEW SPECIALTY PHARMA DIVES INTO COMPETITIVE MIGRAINE MARKET |
|
| 1/29/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
ALTEA REPORTS POSITIVE PHASE I RESULTS FOR BASAL INSULIN PATCH |
|
| 1/26/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
PHARMION SUBMITS EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR THALIDOMIDE PHARMION(R) FOR UNTREATED MULTIPLE MYELOMA |
|
| 1/24/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
VANDA PHARMACEUTICALS ANNOUNCES PRICING OF FOLLOW-ON OFFERING OF 3,800,000 SHARES OF COMMON STOCK |
|
| 1/22/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
IOMAI AWARDED FUNDING TO DEVELOP DOSE-SPARING PATCH FOR USE IN AN INFLUENZA PANDEMIC |
|
| 1/19/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
CEREXA TO BE ACQUIRED BY FOREST LABS FOR $480 MILLION PLUS POTENTIAL $100 MILLION IN MILESTONES |
|
| 1/5/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
NEOSE TECHNOLOGIES PRESENTS POSITIVE PHASE I NE-180 CLINICAL TRIAL DATA |
|
| 1/5/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
FIVEPRIME ENTERS OSTEOARTHRITIS AND PULMONARY FIBROSIS COLLABORATION WITH CENTOCOR |
|
| 1/3/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
ALIMERA RECEIVES U.S. FDA APPROVAL TO MARKET ALAWAY FOR EYE ITCH RELIEF |
|
| 1/2/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
SOMAXON REPORTS RESULTS NOT SIGNIFICANT IN TRIAL OF ORAL NALMEFENE IN PATHOLOGICAL GAMBLING |
|
| 1/2/2007 |
|
|
more
|
| |
| |
|
|
| |
| |
ALIMERA SCIENCES COMPLETES SECOND TRANCHE OF SERIES B FINANCING, RECEIVES $15.9 MILLION |
|
| 12/22/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
NIPPON SHINYAKU, PHARMION ANNOUNCE LICENSE AGREEMENT FOR VIDAZA FOR MYELODYSPLASTIC SYNDROMES |
|
| 12/22/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
BAUSCH & LOMB BUYS ALIMERA PRODUCT LINE |
|
| 12/20/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN THERAPEUTICS FILES REGISTRATION STATEMENT FOR PROPOSED INITIAL PUBLIC OFFERING |
|
| 12/20/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
SOMAXON'S SILENOR DEMONSTRATES POSITIVE RESULTS IN LONG-TERM PHASE 3 TRIAL IN ELDERLY PATIENTS WITH INSOMNIA |
|
| 12/18/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
FOREST LABORATORIES TO ACQUIRE ANTIBIOTIC FIRM CEREXA FOR $480 MILLION |
|
| 12/15/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
PHARMION CANCER THERAPY INDUCES CLINICAL RESPONSE |
|
| 12/13/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
AESTHETIC SCIENCES COMPLETES SERIES-A $6 MILLION FUNDING |
|
| 11/28/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN THERAPEUTICS COMPLETES $30MILLION SERIES C FINANCING |
|
| 11/22/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
PHARMION AND NIPPON SHINYAKU ANNOUNCE LICENSING AGREEMENT FOR VIDAZA IN JAPAN |
|
| 11/21/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
SOMAXON'S SILENOR DEMONSTRATES POSITIVE RESULTS IN THIRD PHASE 3 TRIAL IN INSOMNIA |
|
| 11/20/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
VANDA PHARMACEUTICALS VEC-162 DEMONSTRATES POSITIVE RESULTS IN A PHASE III TRANSIENT INSOMNIA CLINICAL TRIAL |
|
| 11/16/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
NEOSE ANNOUNCES INITIATION OF PHASE I TRIAL OF GLYCOPEG-GCSF |
|
| 11/9/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN ANNOUNCES ISSUANCE OF BROAD PATENTS COVERING COMPOSITION OF ITS LEAD ANTI-OBESITY COMPOUNDS |
|
| 11/9/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
SKINMEDICA AND GALDERMA TO CO-PROMOTE DESONATE |
|
| 11/7/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
NOVACEA INITIATES PHASE I/II OF AQ4N IN GLIOBLASTOMA MULTIFORME |
|
| 11/1/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
NOVACEA INITIATES PHASE I/II TRIAL OF AQ4N IN GLIOBLASTOMA MULTIFORME |
|
| 11/1/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
SOMAXON'S SILENOR DEMONSTRATES POSITIVE PHASE III RESULTS IN TRANSIENT INSOMNIA |
|
| 10/24/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
SKINMEDICA ANNOUNCES FDA APPROVAL OF DESONATE GEL FOR ATOPIC DERMATITIS |
|
| 10/23/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN REPORTS POSITIVE PHASE II RESULTS FOR EXCALIA COMBINATION THERAPY TO TREAT OBESITY |
|
| 10/23/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
NORTHSTAR NEUROSCIENCE REPORTS CLINICAL TRIAL MILESTONES FOR THE THIRD QUARTER 2006 |
|
| 10/10/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
CODA THERAPEUTICS ANNOUNCES SERIES A FINANCING |
|
| 10/10/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN THERAPEUTICS REPORTS POSITIVE 24-WEEK RESULTS FOR CONTRAVE(TM) PHASE III OBESITY TREATMENT STUDY |
|
| 9/27/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
PHARMION & GPC BIOTECH ANNOUNCE POSITIVE RESULTS FROM THE SATRAPLATIN PIVOTAL PHASE 3 TRIAL AND ACHIEVEMENT OF THE PROGRESSION-FREE SURVIVAL ENDPOINT |
|
| 9/25/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
NOVACARDIA RAISES $48 MILLION IN SERIES B - DAVID G. LOWE, PH.D. AND NINA KJELLSON JOIN BOARD OF DIRECTORS |
|
| 9/25/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
CEREXA REPORTS POSITIVE TOP-LINE RESULTS FOR PHASE 2 CLINICAL TRIAL OF CEFTAROLINE |
|
| 8/2/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
ESPRIT PHARMA SUCCESSFULLY COMPLETES A SERIES B FINANCING, RAISING IN EXCESS OF $90 MILLION |
|
| 8/2/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
CELATOR ANNOUNCES POSITIVE EUROPEAN PATENT DECISION FOR COMBIPLEX(TM) |
|
| 7/17/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
VOLCANO CORPORATION ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING |
|
| 6/14/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN REPORTS POSITIVE PHASE II RESULTS FOR CONTRAVE COMBINATION-THERAPY TO TREAT OBESITY |
|
| 6/10/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
NOVACEA’S IPO ADDING $40M FOR LATE-STAGE CLINICAL WORK |
|
| 5/10/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
NORTHSTAR NEUROSCIENCE HAS STRONG IPO DEBUT |
|
| 5/5/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
IOMAI CORP. TRIAL SHOWS DRY VACCINE PATCH IS EFFECTIVE |
|
| 5/1/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
FIVEPRIME AND BOEHRINGER INGELHEIM INITIATE RHEUMATOID ARTHRITIS COLLABORATION |
|
| 4/26/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
VANDA PHARMACEUTICALS ANNOUNCES INITIAL PUBLIC OFFERING |
|
| 4/12/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
Somaxon Pharmaceuticals Announces Positive Phase III Results With Silenor |
|
| 4/10/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
TARGETRX UNVEILS FIRST INDUSTRY ANALYSIS LINKING PHARMACEUTICAL SALES FORCE EFFECTIVENESS WITH PHYSICIAN PRESCRIBING |
|
| 3/20/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
CEREXA'S PPI-0903 RECEIVES FDA FAST TRACK STATUS |
|
| 3/15/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
OREXIGEN THERAPEUTICS APPOINTS DR. GARY TOLLEFSON CEO |
|
| 3/8/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
TERUMO ANNOUNCES ACQUISITION OF MICROVENTION |
|
| 2/28/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
SANTARUS RECEIVES FDA APPROVAL FOR ZEGERID CAPSULES |
|
| 2/27/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
COLUCID PHARMACEUTICALS ANNOUNCES $16.5 MILLION SERIES A FINANCING |
|
| 1/17/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
SAN DIEGO BIOTECH GENEOHM ACQUIRED: MEDICAL DEVICE FIRM IS PAYING $230 MILLION |
|
| 1/11/2006 |
|
|
more
|
| |
| |
|
|
| |
| |
Domain Associates, LLC today announced the promotions of three members of the Domain professional staff |
|
| 12/7/2005 |
|
|
more
|
| |
| |
|
|
| |
| |
TargetRx Wins Eastern Technology Council's Enterprise Award for Life Sciences Growth Company of the Year |
|
| 11/2/2005 |
|
|
more
|
| |
| |
|
|
| |
| |
Cerexa initiates Phase II clinical trial of PPI-0903 |
|
| 10/19/2005 |
|
|
more
|
| |
| |
|
|
| |
| |
Esprit Pharma Acquires North American Rigths to Rights to Estrasorb® Topical Emulsion |
|
| 10/18/2005 |
|
|
more
|
| |
| |
|
|
| |
| |
Volcano Corporation Announces FDA Clearance of the Revolution™ 45 MHz IVUS Imaging Catheter |
|
| 10/12/2005 |
|
|
more
|
| |
| |
|
|
| |
| |
Somaxon Pharmaceuticals Files for Initial Public Offering |
|
| 10/7/2005 |
|
|
more
|
| |
| |
|
|
| |
| |
Alimera Sciences Initiates Phase III Trial for Diabetic Macular Edema |
|
| 10/3/2005 |
|
|
more
|
| |
| |
|
|
| |
| |
Verus Pharmaceuticals Announces U.S. Launch of Twinject for Anaphylaxis |
|
| 8/16/2005 |
|
|
more
|
| |
| |
|
|
| |
| |
NuVasive Acquires Advanced Commercialized Cervical Plate |
|
| 6/6/2005 |
|
|
more
|
| |
| |
|
|
| |
| |
Somaxon Pharmaceuticals, Inc. Announces $65 Million Financing |
|
| 6/6/2005 |
|
|
more
|
| |
| |
|
|
| |
| |
Johnson & Johnson Announces Agreement to Acquire Peninsula Pharmaceuticals, Inc. |
|
| 4/19/2005 |
|
|
more
|
| |
| |
|
|
| |
| |
OmniSonics' OmniWaveTM Receives 2005 Medical Thrombectomy Technology Innovation of the Year Award |
|
| 3/16/2005 |
|
|
more
|
| |
| |
|
|
| |
| |
Venture Wire Highlights Recent Successful Exits by Domain |
|
| 2/3/2005 |
| |
|
more
|
| |
| |
|
|
| |
| |
Valeant Pharma to Buy Xcel Pharma |
|
| 2/2/2005 |
| |
|
more
|
| |
| |
|
|
| |
| |
Protein Design Labs to Acquire ESP Pharma for $475 Million in Cash & Stock |
|
| 1/25/2005 |
| |
|
more
|
| |
| |
|
|
| |
| |
3F Therapeutics Celebrates First Human Implant of Sutureless Heart Valve |
|
| 1/18/2005 |
| |
|
more
|
| |
| |
|
|
| |
| |
Somaxon Announces Positive Results in a Phase II Insomnia Study |
|
| 1/14/2005 |
| |
|
more
|
| |
| |
|
|
| |
| |
Santarus Receives FDA Approval for ZEGERID 40mg Powder for Suspension |
|
| 12/22/2004 |
| |
|
more
|
| |
| |
|
|
| |
| |
Proxima Announces Additional Reimbursement Codes for MammoSite System |
|
| 12/16/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
Boston Scientific Announces Strategic Alliance with Reva Medical, Inc. |
|
| 11/16/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
GeneOhm Sciences and Infectio Diagnostic Announce Plans to Merge |
|
| 10/21/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
IntraLase Completes IPO |
|
| 10/7/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
Peninsula Completes Phase I Trial for PPI-0903 - A Novel Cephalosporin |
|
| 10/7/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
Proxima Presents First Three-Year Data on MammoSite |
|
| 10/4/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
Exelixis Agrees to Acquire X-Ceptor |
|
| 9/28/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
Pharmion Increases Vidaza Sales Guidance |
|
| 9/27/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
Novacea Begins Phase I Trial of Novel Cancer Agent |
|
| 9/23/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
MitoKor Acquired by Micrologix |
|
| 8/31/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
Conforma Enters the Clinic with HSP90 Inhibitor for Cancer |
|
| 8/2/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
Neuropace Approach to Epilepsy Detailed in NY Times |
|
| 5/24/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
Proxima's Breast Cancer Treatment Featured in Wall Street Journal |
|
| 4/28/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
Skin Medica Raises $25.8 Million |
|
| 3/2/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
Auxeris In-licenses Drug Candidate for Osteoporosis |
|
| 1/14/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
Domain Raises Sixth Venture Fund |
|
| 1/6/2004 |
|
|
more
|
| |
| |
|
|
| |
| |
Inspire Added to Nasdaq Biotech Index |
|
| 11/24/2003 |
|
|
more
|
| |
| |
|
|
| |
| |
Pharmion Completes IPO |
|
| 11/6/2003 |
|
|
more
|
| |
| |
|
|
| |
| |
Time Magazine Discusses Cardiac Science's Life-saving Technology |
|
| 6/9/2003 |
|
|
more
|
| |
| |
|
|
| |
| |
Domain's Role in Founding Trimeris Profiled in Raleigh News and Observer |
|
| 3/16/2003 |
|
|
more
|
| |
| |
|
|
| |
|
| |
|
|
| |
|
